IPO13

Across TCGA pan-cancer cohorts, IPO13 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IPO13 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IPO13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IPO13 expression acts as an unfavorable survival marker.

HNSC, UCEC, and PDAC are the cancer types where IPO13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.659	0.907	.001	24	view →
UCEC	DFS	Quartile	All	0.870	1.000	.013	18	view →
PDAC	OS	Quartile	All	0.377	0.663	.003	12	view →
GBM	OS	Quartile	All	0.687	0.953	.012	5	view →
CCRCC	DFS	Quartile	II,III,IV	0.123	0.904	.024	3	view →
LUAD	DFS	Median	All	0.856	0.942	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IPO13–HNSC (DFS)

Open the HNSC breakdown →